The Pacer Metaurus US Large Cap Dividend Multiplier 400 ETF (QDPL) amplifies dividend exposure through futures, performing well only when actual dividends significantly exceed expectations, making its returns dependent on less predictable market conditions. In contrast, the SPYI ETF generates income through covered call spreads, benefiting from volatility and time decay, which allows it to deliver steadier returns across various market environments, including range-bound, declining, or moderately rising markets. Historical data shows SPYI keeps pace during many bullish periods and outperforms in slower markets, while QDPL's advantage is mainly in strong, dividend-beating scenarios. Given a forward outlook of slower growth and fewer dividend surprises, SPYI's versatility justifies an overweight position, whereas QDPL is recommended as a Hold due to its conditional and less reliable outperformance.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
